Artelo Biosciences (ARTL) Share-based Compensation (2017 - 2025)

Artelo Biosciences (ARTL) has reported Share-based Compensation for 9 consecutive years, with $368000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Share-based Compensation rose 83.08% year-over-year to $368000.0 in Q4 2025; TTM through Dec 2025 was $1.4 million, a 14.62% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, up 71.0% from the prior year.
• Share-based Compensation was $368000.0 for Q4 2025 at Artelo Biosciences, down from $746086.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $519.1 million in Q3 2023 and troughed at $201000.0 in Q4 2024.
• A 5-year average of $54.8 million and a median of $746086.0 in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 85419.77% in 2023 and sank 99.85% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $2.9 million in 2021, then slumped by 78.74% to $608000.0 in 2022, then plunged by 63.98% to $219000.0 in 2023, then retreated by 8.22% to $201000.0 in 2024, then jumped by 83.08% to $368000.0 in 2025.
• The last three Share-based Compensation figures came in at $368000.0 (Q4 2025), $746086.0 (Q3 2025), and $806564.0 (Q2 2025), per Business Quant data.